×
About 943 results

ALLMedicine™ Hypereosinophilic Syndrome Center

Research & Reviews  312 results

A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
https://clinicaltrials.gov/ct2/show/NCT04191304

Feb 3rd, 2023 - This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase 3 study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic s...

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
https://clinicaltrials.gov/ct2/show/NCT05334368

Feb 2nd, 2023 - This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis ...

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

Jan 26th, 2023 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Genomics of PDGFR-rearranged hypereosinophilic syndrome.
https://doi.org/10.1182/bloodadvances.2022009061
Blood Advances; Rheinbay E, Qi M et. al.

Jan 19th, 2023 - Genomics of PDGFR-rearranged hypereosinophilic syndrome.|2023|Rheinbay E,Qi M,Bouyssou J,Oler AJ,Thumm L,|

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
https://clinicaltrials.gov/ct2/show/NCT04965636

Jan 11th, 2023 - The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.

see more →

Drugs  21 results see all →

Clinicaltrials.gov  27 results

A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
https://clinicaltrials.gov/ct2/show/NCT04191304

Feb 3rd, 2023 - This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase 3 study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic s...

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
https://clinicaltrials.gov/ct2/show/NCT05334368

Feb 2nd, 2023 - This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis ...

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

Jan 26th, 2023 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
https://clinicaltrials.gov/ct2/show/NCT04965636

Jan 11th, 2023 - The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.

Mepolizumab in Episodic Angioedema With Eosinophilia
https://clinicaltrials.gov/ct2/show/NCT04128371

Nov 3rd, 2022 - Episodic angioedema with eosinophilia (EAE), also known as Gleich s Syndrome,is a rare disorder characterized by recurrent episodes of urticaria, fever, angioedema, weight gain and dramatic eosinophilia that occur at 3- to 6-week intervals and res...

see more →

News  9 results

Next Generation of PDGFR Inhibitors Makes Headway in GIST
https://www.onclive.com/view/next-generation-of-pdgfr-inhibitors-makes-headway-in-gist

May 25th, 2021 - Dysregulated platelet-derived growth factor receptor (PDGFR) signaling is implicated in a number of cancer types and is among the targets of many FDA-approved multikinase inhibitors.1,2 Despite the success of these drugs in a range of malignancies...

Dr. Mesa on Upcoming Updates to NCCN Guideline for MPNs
https://www.onclive.com/view/dr-mesa-on-upcoming-updates-to-nccn-guideline-for-mpns

Dec 20th, 2020 - Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs). The NCCN Guidelines for Myeloproliferative Neoplasms (version 1.2017), which include t...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.staging.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

CHMP recommends approval of generic imatinib
https://www.mdedge.com/hematology-oncology/article/185423/cythemias/chmp-recommends-approval-generic-imatinib
HT Staff

Sep 18th, 2017 - Photo by Patrick Pelletier Imatinib tablet cut with a pill splitter The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Imatinib Teva B. V.

see more →

Patient Education  8 results see all →